UK Markets closed

Genmab A/S (GNMSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
392.75-1.55 (-0.39%)
At close: 03:50PM EST
Full screen
Trade prices are not sourced from all markets
Previous close394.30
Bid0.00 x 0
Ask0.00 x 0
Day's range389.00 - 392.75
52-week range260.25 - 470.50
Avg. volume832
Market cap25.906B
Beta (5Y monthly)0.66
PE ratio (TTM)33.55
EPS (TTM)11.71
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est481.51
  • Globe Newswire

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

    Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio

  • Zacks

    GILD or GMAB: Which Is the Better Value Stock Right Now?

    GILD vs. GMAB: Which Stock Is the Better Value Option?

  • Globe Newswire

    Correction to Company Announcement No. 1 of January 3, 2023

    Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse, acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The corr